Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Metastatic Pancreatic Cancer
NCT04542291Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dapagliflozin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Primary endpoint: Tolerability as Measured by Number of Participants With Related Adverse Events at 3 months. Started Feb 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04542291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542291.